OBJECTIVES: The aim of this study was to provide an overview of the presenting features, etiologies, and outcomes of children enrolled in the Drug-induced Liver Injury Network (DILIN) prospective and retrospective studies. METHODS: Consecutive definite, highly likely, or probable cases in children enrolled into the ongoing DILIN prospective and retrospective studies between September 2004 and February 2017 were reviewed. RESULTS: Fifty-seven cases were adjudicated as definite (14), highly likely (30), or probable (13) DILI. Median age was 14.3 years (1.7-17.9), 67% female, and 82% Caucasian. At DILI onset, 82% had hepatocellular injury with a median alanine aminotransferase of 411 U/L (33-4185), alkaline phosphatase 203 U/L (62-1177), and total bilirubin 3.3 mg/dL (0.2-33.9). The median duration of suspect medication use was 55 days (1-2789) and the most frequently implicated individual agents were minocycline (n = 11) and valproate (n = 6). Sixty-three percent were hospitalized and 3 (5%) underwent liver transplant within 1 month of DILI onset. Among 46 children followed for at least 6 months, 8 (17%) met criteria for chronic DILI with 6 of them having persistent liver injury at 24 months of follow-up. A genome-wide association study in 39 Caucasian children focusing on regions associated with pediatric cholestatic liver disease failed to demonstrate any single nucleotide polymorphism associated with DILI susceptibility or outcome. CONCLUSIONS: Antimicrobials (51%) and antiepileptic drugs (21%) are the most frequently implicated agents in pediatric DILI patients. Although the majority of cases are self-limited, there is potential for serious morbidity including acute liver failure, chronic liver injury, and death.
OBJECTIVES: The aim of this study was to provide an overview of the presenting features, etiologies, and outcomes of children enrolled in the Drug-induced Liver Injury Network (DILIN) prospective and retrospective studies. METHODS: Consecutive definite, highly likely, or probable cases in children enrolled into the ongoing DILIN prospective and retrospective studies between September 2004 and February 2017 were reviewed. RESULTS: Fifty-seven cases were adjudicated as definite (14), highly likely (30), or probable (13) DILI. Median age was 14.3 years (1.7-17.9), 67% female, and 82% Caucasian. At DILI onset, 82% had hepatocellular injury with a median alanine aminotransferase of 411 U/L (33-4185), alkaline phosphatase 203 U/L (62-1177), and total bilirubin 3.3 mg/dL (0.2-33.9). The median duration of suspect medication use was 55 days (1-2789) and the most frequently implicated individual agents were minocycline (n = 11) and valproate (n = 6). Sixty-three percent were hospitalized and 3 (5%) underwent liver transplant within 1 month of DILI onset. Among 46 children followed for at least 6 months, 8 (17%) met criteria for chronic DILI with 6 of them having persistent liver injury at 24 months of follow-up. A genome-wide association study in 39 Caucasian children focusing on regions associated with pediatric cholestatic liver disease failed to demonstrate any single nucleotide polymorphism associated with DILI susceptibility or outcome. CONCLUSIONS: Antimicrobials (51%) and antiepileptic drugs (21%) are the most frequently implicated agents in pediatric DILI patients. Although the majority of cases are self-limited, there is potential for serious morbidity including acute liver failure, chronic liver injury, and death.
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: M Isabel Lucena; Mariam Molokhia; Yufeng Shen; Thomas J Urban; Guruprasad P Aithal; Raúl J Andrade; Christopher P Day; Francisco Ruiz-Cabello; Peter T Donaldson; Camilla Stephens; Munir Pirmohamed; Manuel Romero-Gomez; Jose Maria Navarro; Robert J Fontana; Michael Miller; Max Groome; Emmanuelle Bondon-Guitton; Anita Conforti; Bruno H C Stricker; Alfonso Carvajal; Luisa Ibanez; Qun-Ying Yue; Michel Eichelbaum; Aris Floratos; Itsik Pe'er; Mark J Daly; David B Goldstein; John F Dillon; Matthew R Nelson; Paul B Watkins; Ann K Daly Journal: Gastroenterology Date: 2011-04-12 Impact factor: 22.682
Authors: Don C Rockey; Leonard B Seeff; James Rochon; James Freston; Naga Chalasani; Maurizio Bonacini; Robert J Fontana; Paul H Hayashi Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Russell P Saneto; Inn-Chi Lee; Mary Kay Koenig; Xinhua Bao; Shao-Wen Weng; Robert K Naviaux; Lee-Jun C Wong Journal: Seizure Date: 2010-02-06 Impact factor: 3.184
Authors: Catherine Sgro; François Clinard; Kader Ouazir; Henry Chanay; Christian Allard; Christian Guilleminet; Claude Lenoir; Alain Lemoine; Patrick Hillon Journal: Hepatology Date: 2002-08 Impact factor: 17.425
Authors: Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: M Isabel Lucena; Raúl J Andrade; Neil Kaplowitz; Miren García-Cortes; M Carmen Fernández; Manuel Romero-Gomez; Miguel Bruguera; Hacibe Hallal; Mercedes Robles-Diaz; Jose F Rodriguez-González; Jose Maria Navarro; Javier Salmeron; Pedro Martinez-Odriozola; Ramón Pérez-Alvarez; Yolanda Borraz; Ramón Hidalgo Journal: Hepatology Date: 2009-06 Impact factor: 17.425
Authors: Joanna D Stewart; Rita Horvath; Enrico Baruffini; Iliana Ferrero; Stefanie Bulst; Paul B Watkins; Robert J Fontana; Christopher P Day; Patrick F Chinnery Journal: Hepatology Date: 2010-11 Impact factor: 17.425
Authors: K E Price; R E Pearce; U C Garg; B A Heese; L D Smith; J E Sullivan; M J Kennedy; J F Bale; R M Ward; T K H Chang; F S Abbott; J S Leeder Journal: Clin Pharmacol Ther Date: 2011-05-04 Impact factor: 6.875
Authors: Tracy L Sandritter; Jennifer L Goldman; Clayton J Habiger; James F Daniel; Jennifer Lowry; Ryan T Fischer Journal: Sci Rep Date: 2019-12-02 Impact factor: 4.379